Cargando…

Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation

OBJECTIVE: To evaluate the efficiency, postoperative hysterectomy rate, and influencing factors for therapeutic effect of the NovaSure endometrial ablation procedure in abnormal uterine bleeding (AUB). METHODS: We conducted a retrospective cohort study of 2152 patients from the Department of Gynecol...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Hui, Wan, Yajun, Yi, Shuijing, Zeng, Fei, Sun, Xin, Yang, Yimin, Xiao, Songshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540028/
https://www.ncbi.nlm.nih.gov/pubmed/34653258
http://dx.doi.org/10.1002/ijgo.13983
_version_ 1784803620673290240
author Xie, Hui
Wan, Yajun
Yi, Shuijing
Zeng, Fei
Sun, Xin
Yang, Yimin
Xiao, Songshu
author_facet Xie, Hui
Wan, Yajun
Yi, Shuijing
Zeng, Fei
Sun, Xin
Yang, Yimin
Xiao, Songshu
author_sort Xie, Hui
collection PubMed
description OBJECTIVE: To evaluate the efficiency, postoperative hysterectomy rate, and influencing factors for therapeutic effect of the NovaSure endometrial ablation procedure in abnormal uterine bleeding (AUB). METHODS: We conducted a retrospective cohort study of 2152 patients from the Department of Gynecology at the Third Xiangya Hospital, CSU from October 2010 to December 2018. RESULTS: From the first year to the eighth year after operation, annual effective rate was above 95.24%, and the differences were not statistically significant. There are statistically significant differences between the effective and ineffective groups with regard to age, intrauterine polyps, total length of the uterus, systemic coagulation disorder, and preoperative hemoglobin. A multivariate logistic regression analysis showed that the risk factors associated with systemic coagulation disorders (P = 0.027) and high total uterine length (P = 0.003) affected NovaSure efficacy in the treatment of AUB. By December 2019, the postoperative hysterectomy rate was 1.86% (40/2152) and the complication rate was 1.67% (36/2152). CONCLUSION: NovaSure is a reliable treatment for AUB and serious medical complications because of its simple operation, low amount of bleeding, quick postoperative recovery, and safe and effective short‐term and long‐term efficacy. However, it should be carefully selected for patients with a total uterus length exceeding 10 cm.
format Online
Article
Text
id pubmed-9540028
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95400282022-10-14 Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation Xie, Hui Wan, Yajun Yi, Shuijing Zeng, Fei Sun, Xin Yang, Yimin Xiao, Songshu Int J Gynaecol Obstet Clinical Articles OBJECTIVE: To evaluate the efficiency, postoperative hysterectomy rate, and influencing factors for therapeutic effect of the NovaSure endometrial ablation procedure in abnormal uterine bleeding (AUB). METHODS: We conducted a retrospective cohort study of 2152 patients from the Department of Gynecology at the Third Xiangya Hospital, CSU from October 2010 to December 2018. RESULTS: From the first year to the eighth year after operation, annual effective rate was above 95.24%, and the differences were not statistically significant. There are statistically significant differences between the effective and ineffective groups with regard to age, intrauterine polyps, total length of the uterus, systemic coagulation disorder, and preoperative hemoglobin. A multivariate logistic regression analysis showed that the risk factors associated with systemic coagulation disorders (P = 0.027) and high total uterine length (P = 0.003) affected NovaSure efficacy in the treatment of AUB. By December 2019, the postoperative hysterectomy rate was 1.86% (40/2152) and the complication rate was 1.67% (36/2152). CONCLUSION: NovaSure is a reliable treatment for AUB and serious medical complications because of its simple operation, low amount of bleeding, quick postoperative recovery, and safe and effective short‐term and long‐term efficacy. However, it should be carefully selected for patients with a total uterus length exceeding 10 cm. John Wiley and Sons Inc. 2021-11-16 2022-08 /pmc/articles/PMC9540028/ /pubmed/34653258 http://dx.doi.org/10.1002/ijgo.13983 Text en © 2021 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Articles
Xie, Hui
Wan, Yajun
Yi, Shuijing
Zeng, Fei
Sun, Xin
Yang, Yimin
Xiao, Songshu
Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title_full Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title_fullStr Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title_full_unstemmed Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title_short Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation
title_sort clinical analysis of 2152 cases of abnormal uterine bleeding treated by novasure endometrial ablation
topic Clinical Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540028/
https://www.ncbi.nlm.nih.gov/pubmed/34653258
http://dx.doi.org/10.1002/ijgo.13983
work_keys_str_mv AT xiehui clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT wanyajun clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT yishuijing clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT zengfei clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT sunxin clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT yangyimin clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation
AT xiaosongshu clinicalanalysisof2152casesofabnormaluterinebleedingtreatedbynovasureendometrialablation